AccessibilityHelp

Medicenna Therapeutics(OTC) MDNAF

Market Cap$23.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-80%
5 Year-87%
1 Year-60%
1 Month+8%
$0.30
-2.22%
-0.01Today
Medicenna Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.312026-10-23
Medicenna Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.49%USD 0.302026-10-16
1 month+7.6%USD 0.292026-09-23
3 month+24.19%USD 0.252026-07-24
Year to date-54.65%USD 0.682025-12-31
1 year-59.65%USD 0.762025-10-23
3 year+12.04%USD 0.272023-10-24
5 year-87.28%USD 2.412021-10-22
Since inception-79.5%USD 1.502017-09-20

Medicenna Therapeutics Financials at a Glance

Market Cap

$23.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$13.43

EPS (TTM)

-$0.16

P/E Ratio

-1.92

Dividend

$0.00

Beta (Volatility)

0.92 (Low)

Price

$0.30

Volume

13,600

Open

$0.31

Previous Close

$0.31

Daily Range

$0.30 - $0.31

52-Week Range

$0.23 - $1.43

Estimated Earnings Date

Nov 12, 2026

MDNAF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medicenna Therapeutics

Medicenna Therapeutics Corp. is an innovative immunotherapy company focused on developing Superkines and empowered Superkines for cancer treatment and other diseases. The company’s lead candidate, MDNA55, has shown promise in clinical trials for recurrent glioblastoma and is advancing through various stages of development.

Products and Services
  • MDNA55: Targeted therapy for recurrent glioblastoma
  • MDNA11: Enhanced IL-2 designed to boost immune cell activity
  • MDNA209: IL-2 antagonist for autoimmune conditions
Growth Outlook
  • MDNA55 has completed a Phase IIb trial, indicating strong clinical progress
  • Pipeline includes multiple candidates targeting various cancers and autoimmune diseases
  • Proprietary BiSKITs platform enhances potential for custom Superkine development
Financial Highlights
  • Recent quarterly net income of -$3.72 million, reflecting ongoing R&D investments
  • Cash and cash equivalents of $25.69 million as of September 30, 2023
  • Operating expenses increased to $5.44 million in Q2 2023, driven by R&D efforts
Medicenna Therapeutics Corp. is positioned in the biotechnology sector, focusing on groundbreaking therapies that leverage the immune system to combat cancer and other diseases. The company’s innovative approach, particularly with MDNA55, highlights its commitment to advancing cancer treatment options. The ongoing development of its pipeline, including MDNA11 and MDNA209, showcases the potential for significant growth in addressing unmet medical needs. Financially, while the company is currently operating at a loss, the substantial cash reserves provide a buffer for continued research and development, which is crucial for long-term success in the competitive biotech landscape.
AI Generated • Oct 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

20

CEO

Fahar Merchant, PhD

Website

www.medicenna.com

Headquarters

Toronto, ON M4W 3E2, CA

MDNAF Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-225.59%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-52.08%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$23.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

77.62M

Volume

13.60K

Avg. Volume

44.28K

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$2.35M

EBITDA

-CA$2.34M

Operating Cash Flow

CA$0.00

Capital Expenditure

CA$0.00

Free Cash Flow

CA$0.00

Cash & ST Invst.

N/A

Total Debt

N/A

Medicenna Therapeutics Performance Analysis

Medicenna Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31CAD 0N/A
20242024-03-31CAD 0N/A
20252025-03-31CAD 0N/A
20262026-03-31CAD 0N/A
Medicenna Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22020-06-30N/A
Medicenna Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31CAD -0.12-64.6%
20242024-03-31CAD -0.27131.1%
20252025-03-31CAD -0.11-59.2%
20262026-03-31CAD -0.1644.6%
Medicenna Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22020-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2020YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$23.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.19M

N/A

Employees

20

N/A

Net Income

-CA$2.35M

N/A

EBITDA

-CA$2.34M

N/A

Quarterly Fundamentals

Name
Q2 2020YOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

CA$0.00

N/A

Operating Cash Flow

CA$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NXTCNextCure, Inc.
$5.23+6.63%
IMMPImmutep Limited
$3.10-3.13%
HOWLWerewolf Therapeutics, Inc.
$0.98+0.05%
XLOXilio Therapeutics, Inc.
$7.31-3.43%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$12.59-16.95%
EWZiShares - iShares Msci Brazil ETF
$34.15-19.82%
ITUBItaú Unibanco
$7.70-20.37%
XPXP
$15.71-48.36%

Questions About MDNAF

What is the current price of Medicenna Therapeutics?

Medicenna Therapeutics is trading at $0.30 per share.

What is the 52-week range for Medicenna Therapeutics?

Over the past 52 weeks, Medicenna Therapeutics has traded between $0.23 and $1.43.

How much debt does Medicenna Therapeutics have?

As of the most recent reporting period, Medicenna Therapeutics reported total debt of CA$73.30K.

How much cash does Medicenna Therapeutics have on hand?

Medicenna Therapeutics reported CA$4.01M in cash and cash equivalents in its most recent financial results.

What is Medicenna Therapeutics’s dividend yield?

Medicenna Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services